Eloxx Pharmaceuticals Provides Program Updates On ELX-02 And ZKN-013
Portfolio Pulse from Benzinga Newsdesk
Eloxx Pharmaceuticals has submitted an Investigational New Drug (IND) application to the U.S. FDA for ELX-02 for the treatment of Alport syndrome. All 3 Alport patients treated with ELX-02 had disease regression, suggesting clinical benefit with longer treatment duration. There is significant strategic interest in ZKN-013 following FDA approval to start Phase 1 trial.

September 07, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eloxx Pharmaceuticals' IND application for ELX-02 and the positive results from its use in Alport syndrome patients could potentially boost the company's stock. The FDA approval for Phase 1 trial of ZKN-013 also adds to the positive outlook.
The submission of the IND application to the FDA for ELX-02 and the positive results from its use in Alport syndrome patients could potentially boost Eloxx Pharmaceuticals' stock. The FDA approval for the Phase 1 trial of ZKN-013 also adds to the positive outlook for the company, as it indicates progress in the company's product pipeline.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100